Business Update Neutral

2026-05-29 15:20

Laurus Labs announced its schedule for analyst and institutional investor meetings. The company will participate in one-on-one and group meetings on June 05, 2026, with BofA Healthcare Tour, and on June 10, 2026, with Macquarie Healthcare Tour, both in Hyderabad. No Unpublished Price Sensitive Information will be shared during these interactions.

Business Update Positive

2026-05-21 17:40

Laurus Labs announced its schedule for upcoming analyst and institutional investor meetings. The company will participate in the 360 ONE Capital (B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 on May 27, 2026, and the Citi 2026 India Conference on June 04, 2026, both in Mumbai. These will be in-person meetings, and no unpublished price sensitive information will be shared.

Business Update Positive

2026-05-21 17:34

Laurus Labs announced its first-time inclusion in the Dow Jones Best-in-Class (DJ BIC) Indices, specifically the DJBIC World Index, effective May 21, 2026. This recognition highlights the company's strong ESG performance and commitment to sustainable corporate governance. Its S&P Global Corporate Sustainability Assessment (CSA) score improved to 81 out of 100 (from 71 previously) in the pharmaceutical category, reinforcing credibility with global investors.

Business Update Positive

2026-05-05 17:34

Laurus Labs outlined significant plans, including INR 3,000 crores in Capex over the next two years for mid- and large-scale manufacturing, with Unit 7's first commercial validation by March FY27 and peptide manufacturing by Q2 FY27. Management expressed confidence in maintaining or improving EBITDA margins in FY27 and expects strong positive growth in its CDMO segment, targeting 50% of total sales by FY30. Affordable Medicines and non-ARV formulations are also projected for strong growth, with Animal Health expected to contribute meaningfully in FY27. ARV revenues are anticipated to remain constant in absolute terms, leading to a decline in their percentage contribution. R&D spend is expected to be similar to FY26 at 4.1% of sales, with the effective tax rate projected at 25-26%.

Business Update Neutral

2026-04-30 21:47

Laurus Labs Limited announced the availability of the audio recording for its Q4 FY26 Results Conference Call, which was hosted on April 30, 2026. The company provided a web link for accessing the recording.

Routine Neutral

2026-04-30 16:17

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:38

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:37

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:34

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:31

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:27

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:22

New Filing detected. See link for details.

Routine Neutral

2026-04-30 15:17

New Filing detected. See link for details.

Financials Positive

2026-04-28 11:29

Laurus Labs clarified deficiencies in previous financial results submission for Q2 FY26 due to technical issues. The Board approved unaudited financial results for the quarter ended Sep 30, 2025, and an interim dividend of Rs. 0.80 per share (40%) for FY26. Record date is Oct 31, 2025, with payment on or after Nov 12, 2025.

Routine Neutral

2026-04-15 11:46

Laurus Labs Limited submitted the Regulation 74(5) certificate for the quarter ended March 31, 2026. KFin Technologies Limited, the Registrar and Share Transfer Agent, certified that the details of securities dematerialized/rematerialized during the period have been furnished to the Stock Exchanges.

Routine Neutral

2026-04-09 18:45

New Filing detected. See link for details.

Business Update Positive

2026-04-07 17:19

Unsecured creditors of Laurus Synthesis Private Limited and Sriam Labs Private Limited (wholly-owned subsidiaries) approved the Composite Scheme of Arrangement on April 06, 2026. This approval marks a significant milestone, though the scheme remains subject to NCLT and other regulatory approvals.

Ownership Neutral

2026-03-30 19:16

Laurus Labs announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2026. This is in compliance with SEBI (Prohibition of Insider Trading) Regulations.

Governance Neutral

2026-03-12 18:43

Laurus Labs' Board recommended the appointment of S.R. Batliboi & Associates LLP as Statutory Auditors for five years, from the conclusion of the 22nd AGM (2027) until the 27th AGM (2032), subject to shareholder approval. This follows the completion of Deloitte Haskins & Sells LLP's term.

Business Update Neutral

2026-03-11 15:15

Laurus Labs announced an Analyst / Institutional Investor Meeting on March 18, 2026, involving a facility visit and management interaction in Visakhapatnam. The company stated that no Unpublished Price Sensitive Information will be shared during these meetings.

Business Update Neutral

2026-03-06 15:20

Laurus Labs will participate in the Investec India Conference 2026 in Hyderabad from March 12-13, 2026, for group meetings with analysts and institutional investors.

Business Update Positive

2026-02-24 20:39

NCLT approved the Composite Scheme of Arrangement for Laurus Labs Limited and its wholly-owned subsidiaries, Laurus Synthesis Pvt Ltd and Sriam Labs Pvt Ltd. The scheme involves the demerger of LSPL's Unit-1 into Sriam and the amalgamation of the remaining LSPL with Laurus Labs Limited. The order was pronounced on February 24, 2026.

Business Update Positive

2026-02-23 16:24

Laurus Labs was recognized for Sustainability Leadership by S&P Global and featured in the S&P Global Sustainability Yearbook 2026 for strong ESG performance. Its Corporate Sustainability Assessment score improved from 71 to 81, positioning it among the world's most sustainable companies.

Business Update Positive

2026-02-20 18:55

Laurus Labs received an independent ESG Score of 68.6 out of 100 for FY 2025 from SES ESG Research Private Limited, based on publicly available data.

Business Update Neutral

2026-02-17 12:48

Laurus Labs announced its participation in the 17th Annual Kotak Investor Conference on February 24, 2026, in Mumbai, for in-person group meetings with analysts/investors. No Unpublished Price Sensitive Information will be shared during the meeting.

LAURUSLABS

Laurus Labs Limited

Filing History

Unlock Full History